Drug intelligence / Profile preview

amlodipine besylate + tadalafil

Development stage: Unknown
Lead developer: Hanmi Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HCP1302 is a fixed-dose combination drug consisting of amlodipine besylate, a calcium channel blocker, and tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor. It was developed by Hanmi Pharmaceutical for the treatment of both hypertension and erectile dysfunction. The combination leverages the antihypertensive effects of amlodipine with the vasodilatory and erectile function-enhancing properties of tadalafil. Clinical trials have evaluated its efficacy and safety in patients with coexisting hypertension and erectile dysfunction[1][3][4].

Brand names: Amotada
Other names: HCP 1302HCP1302HCP-1302

Targets

LTCC (Voltage-gated calcium channel (L-type))PDE5 (Phosphodiesterase 5A)

Beyond the preview

Go deeper on amlodipine besylate + tadalafil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amlodipine besylate + tadalafil.

Explore the full profile